GlassScriptPhysician profile
Timothy Martin
NPI 1366902934
$3,515.47
in general payments reported to CMS, 2019-2025
23 companies · $228 in 2025
The $228 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $122 · 2023: $539 · 2024: $2,627 · 2025: $228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,804 · Travel and Lodging: $1,589.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,803.94 |
| Travel and Lodging | $1,589.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $2,143.84 | 2024 | Micra |
| Boston Scientific Corporation | $139.61 | 2023-2024 | Watchman Flx |
| Novo Nordisk INC | $135.41 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $110.52 | 2023-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Janssen Pharmaceuticals, INC | $104.64 | 2023-2024 | Xarelto |
| Exact Sciences Corporation | $90.99 | 2023-2024 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.28 | 2022 | |
| Pfizer INC. | $87.28 | 2023-2025 | |
| Cvrx, INC. | $72.89 | 2023-2025 | Barostim Neo System |
| Alnylam Pharmaceuticals INC. | $66.36 | 2022-2024 | Onpattro |
| Amgen INC. | $60.98 | 2023-2025 | Repatha, Otezla, Repatha |
| Novartis Pharmaceuticals Corporation | $59.83 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $57.53 | 2022-2023 | Verquvo, Belsomra, Steglatro |
| Lilly USA, LLC | $45.08 | 2023-2024 | Jardiance, Mounjaro, Zepbound |
| Philips North America LLC | $42.00 | 2024 | (Cm9) Amb Mon & Diag Und |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $41.54 | 2024 | Optimizer |
| Abiomed | $40.21 | 2024 | Impella |
| Bayer Healthcare Pharmaceuticals INC. | $36.15 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $22.93 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $22.86 | 2025 | Attruby |
| Almatica Pharma LLC | $16.90 | 2024 | Teriparatide |
| Abbvie INC. | $14.46 | 2025 | |
| Edwards Lifesciences Corporation | $14.18 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.